Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.829 USD | +2.36% | -6.95% | +15.62% |
04-26 | VolitionRx Limited Announces Board Changes | CI |
04-23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.62% | 68.07M | C | ||
-27.67% | 9.87B | A- | ||
-17.30% | 2.73B | C | ||
-11.15% | 2.24B | - | B- | |
-22.32% | 1.63B | C+ | ||
+59.69% | 1.39B | B- | ||
+23.58% | 771M | C- | ||
-1.31% | 760M | C+ | ||
-28.57% | 516M | C- | ||
+5.37% | 310M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNRX Stock
- Ratings VolitionRx Limited